-
J. Edward Moreno
Posts
Novo says FDA has approved high-dose Wegovy shot
Wegovy HD was the first drug to be approved through the FDA’s new priority voucher system.Source: Sherwood News.
Lilly reports encouraging trial results for its next-gen GLP-1 shot
Patients taking the highest dose of retatrutide lost 16.8% of their body weight after 40 weeks, more than its current bestseller, tirzepatide.Source: Sherwood News.
Optics stocks rise as executives signal more AI-related demand
Optics companies have rallied this year on expectations of higher demand for the components they make.Source: Sherwood News.
AI drone company Swarmer soars on IPO debut
Its technology has been used on the battlefield in Ukraine, and the company’s IPO comes amid the ongoing conflict in Iran.Source: Sherwood News.
Eli Lilly receives its only sell rating from HSBC, which cites smaller market for weight-loss drugs
HSBC also cut its price target to $850 from $1,070. The stock is currently trading around $989.Source: Sherwood News.
Trump says he has ordered all federal agencies to cease use of Anthropic’s products
Trump said agencies like the Department of War will phase out Anthropic’s products over the next six months. Source: Sherwood News.
OpenAI is reportedly working with Pentagon to hash out guardrails amid Anthropic standoff over AI safety
CEO Sam Altman said OpenAI shares Anthropic’s “red lines.” Source: Sherwood News.
Grindr rises after beating earnings, revenue expectations
The company reported earnings results on Thursday. Source: Sherwood News.
How GLP-1s elevated Hims — and brought it back down to earth
Here’s a look at how the company’s GLP-1 business has sent the stock on a wild ride Source: Sherwood News.
Novo Nordisk to slash GLP-1 list prices starting in 2027
Novo said the move will expand access for patients, “specifically those whose out-of-pocket costs are linked to list price, such as individuals with high-deductible health…